Mode
Text Size
Log in / Sign up
N/A N=175 Randomized Single-blind Diagnostic

The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment

PRU · miRNA

Enrolled (actual)
175
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: miRNA — -8.14; -3.46; -7.54; -3.97 fold of change

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
miRNA within 24hr (Procedure); miRNA after 1 week (Procedure); miRNA after 1 month (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Taipei City Hospital
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
miRNA
-8.14; -3.46; -7.54; -3.97

Summary

For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis of medical criteria (clinical guidelines) routine as aspirin + clopidogrel or aspirin + ticagrelor, according to medical guidelines currently no other disposal alternative proposal (unless adverse drug tolerance or bleeding can not be administered); idea of this experiment for acute coronary syndrome or conventional cardiac catheterization after stenting, platelet miRNA expression (miR-96 , miR-200b, miR-495, miR-107) after cardiac catheterization and interventional treatment of clopidogrel or ticagrelor acceptance of platelet reactivity (PRU) correlation values (given clopidogrel or ticagrelor determined by the clinician, the patient follow-up experiment to track only and observation), aims to explore under different platelet reactivity (hyper-reactive or hypo-reactive), their differences in miRNA performance.

Eligibility Criteria

Inclusion Criteria

1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent implantation.

  • DAPT 24 hours after treatment PRU (platelet activity units) values. (Drug unresponsive patients was defined as PRU> 235).

Exclusion Criteria

1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication intolerance.

3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as heart failure patients not suitable for use cilostazol).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02101437). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search